Global TNF Alpha Inhibitors Market Report 2020: Market is Expected to Recover and Reach $42.86 Billion in 2023 - Long-term Forecast to 2025 & 2030
29 mars 2021 04h53 HE
|
Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "TNF Alpha Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. The global...
Global $2.27 Billion Adalimumab, Infliximab and Etanercept Biosimilars Market to 2030
03 févr. 2021 04h43 HE
|
Research and Markets
Dublin, Feb. 03, 2021 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to...
Global Gastrointestinal Drugs Markets, 2019-2020 & 2027: Acid Neutralizers, Antidiarrheal and Laxatives, Anti-inflammatory Drugs, Antiemetic and Antinauseants, Biologics
24 nov. 2020 02h38 HE
|
Research and Markets
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class; Route of Administration; Application; Distribution...
Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China
06 janv. 2020 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm (HK:2181) filed recently a New Drug Application for the Infliximab...
American College of Rheumatology Encourages Safe Adoption of Biosimilars During FDA Public Hearing on CT-P13, a Proposed Biosimilar for Infliximab (Remicade)
10 févr. 2016 14h43 HE
|
American College of Rheumatology
ATLANTA, Feb. 10, 2016 (GLOBE NEWSWIRE) -- During a public meeting held Tuesday by the Food and Drug Administration (FDA)'s Arthritis Advisory Committee to review the license application of CT-P13,...